LivaNova PLC (LIVN) · Nov 4, 2026 · Earnings

LivaNova earnings beat as 2026 guidance rises again

Beat — Adj. EPS $1.23 vs ~$1.06 consensus; revenue $393.1M vs ~$381.1M

LivaNova earnings beat Q3 expectations, with both segments growing above 10% and 2026 revenue and adjusted EPS guidance raised again.

LivaNova is a two-segment medical-device company building growth around Cardiopulmonary products, including the Essenz perfusion system, and Neuromodulation therapies such as VNS for epilepsy. The prior quarter already showed roughly 10% constant-currency growth and another guidance increase, so this filing extends an established execution trend rather than introducing a new strategy.

The quarter cleared expectations on both core measures. Revenue reached $393.1 million, about 3% above the published consensus of roughly $381.1 million, while adjusted diluted EPS of $1.23 was about 16% above the roughly $1.06 consensus. The beat was operationally broad: Cardiopulmonary revenue rose 10.9% and Neuromodulation revenue rose 11.1% year over year. 〔0〕

Q3 2026Q3 2025Consensus
Net revenue (Net Revenue)$393.1M (+9.9%)$357.8M~$381.1M
Adjusted diluted EPS (Income Statement)$1.23 (+10.8%)$1.11~$1.06
Adjusted operating income (Income Statement)$92.3M (+14.8%)$80.4M
FY2026 revenue growth (Guidance)9%-10%8%-9% prior
FY2026 adjusted diluted EPS (Guidance)$4.40-$4.50$4.30-$4.40 prior

Management raised the outlook rather than merely defending it. Full-year constant-currency revenue growth was lifted by 100 basis points to 9%-10%, and adjusted EPS guidance increased by $0.10 at the midpoint to $4.40-$4.50. That is the clearest signal in the filing: the quarter was strong enough to convert current execution into a higher 2026 earnings expectation. 〔1〕

The underlying business is improving, but GAAP earnings remain noisy. Adjusted operating income increased to $92.3 million from $80.4 million, while reported diluted EPS was only $0.11 versus $0.49 a year earlier because of financing and fair-value items. The adjusted result is therefore the cleaner measure of operating progress for this quarter; the statutory number does not overturn the positive read, but it does make headline GAAP EPS less useful.

The filing also adds longer-term commercial support, though not immediate revenue. New Category I CPT codes for the company’s hypoglossal nerve stimulation therapy are expected to become effective January 1, 2028, while 36-month CORE-VNS data showed a 76% median seizure reduction. Those developments strengthen access and clinical support for Neuromodulation, but their financial contribution is still ahead rather than reflected directly in this quarter. 〔2〕

Bottom line: This was a genuine beat with another upward revision to the 2026 outlook, reinforcing that LivaNova’s Cardiopulmonary and Neuromodulation growth is translating into better operating earnings. It strengthens the existing story materially, though it is an acceleration of a trend already visible after the second quarter rather than a wholesale change in direction.

What to watch next

Q4 2026 earnings report, early 2027

Original filing on SEC EDGAR

More LivaNova PLC news

LivaNova earnings beat as 2026 guidance rises again | LIVN Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.